Chava E. Perry

6 Weitzman Street
Tel Aviv, TA, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy

Published: April 04, 2026

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study.

Journal: British journal of haematology

Published: March 31, 2026

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Journal: Cancers

Published: March 30, 2026

Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report.

Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report.

Journal: Case reports in hematology

Published: October 21, 2025

Attenuated antibody responses to respiratory syncytial virus vaccination in hematologic malignancies: impact of anti-CD20 therapy.

Attenuated antibody responses to respiratory syncytial virus vaccination in hematologic malignancies: impact of anti-CD20 therapy.

Journal: Haematologica

Published: September 24, 2025

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

Journal: Haematologica

Published: August 19, 2025

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.

Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting- a retrospective study.

Journal: Annals of hematology

Published: February 25, 2025

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

Journal: Transplantation and cellular therapy

Published: July 31, 2024

Clinical significance of FLC tests in patients without other evidence of hematologic disorder.

Clinical significance of FLC tests in patients without other evidence of hematologic disorder.

Journal: Clinical and experimental medicine

Published: July 02, 2024

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma.

Journal: Hematological oncology

Published: March 05, 2024

Primary Cardiac Lymphoma Patients Presenting With Heart Failure.

Primary Cardiac Lymphoma Patients Presenting With Heart Failure.

Journal: CASE (Philadelphia, Pa.)

Published: November 29, 2023

The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy.

The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy.

Journal: Cancers

Published: October 29, 2023

Showing 1-12 of 83

Last Updated: 09/26/2026